Key Points
- BeOne SVP Chan Henry Lee sold 332 shares on Dec. 11 at $325 (≈$107.9k) and, along with prior October and November transactions, has disposed of about 11,999 shares since Oct., totaling roughly $4.19M.
- Analyst sentiment is broadly positive with 12 Buys, 1 Hold and 1 Sell, a consensus target price of $365.79 (MarketBeat: "Moderate Buy"), while the stock recently opened around $319 and has a 1‑year range of $170.99–$385.22.
- Large institutions have added meaningful positions (e.g., Primecap, Temasek, Marshall Wace) in Q2, and institutional investors now own about 48.55% of the company.
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 332 shares of the stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $325.00, for a total value of $107,900.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Chan Henry Lee also recently made the following trade(s):
- On Wednesday, November 12th, Chan Henry Lee sold 996 shares of BeOne Medicines stock. The shares were sold at an average price of $349.17, for a total value of $347,773.32.
- On Wednesday, October 8th, Chan Henry Lee sold 10,671 shares of BeOne Medicines stock. The stock was sold at an average price of $350.40, for a total value of $3,739,118.40.
BeOne Medicines Stock Performance
Shares of NASDAQ:ONC opened at $319.06 on Friday. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03. BeOne Medicines Ltd. - Sponsored ADR has a 1-year low of $170.99 and a 1-year high of $385.22. The stock has a market capitalization of $37.82 billion, a P/E ratio of 625.61 and a beta of 0.45. The business has a 50-day moving average price of $331.05 and a two-hundred day moving average price of $305.13.
Analyst Ratings Changes
ONC has been the topic of several analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of BeOne Medicines in a report on Wednesday, October 8th. Citigroup upped their target price on shares of BeOne Medicines from $399.00 to $405.00 and gave the company a "buy" rating in a research report on Monday, November 10th. Citizens Jmp raised their price target on BeOne Medicines from $348.00 to $396.00 and gave the stock a "market outperform" rating in a research report on Friday, November 7th. Jefferies Financial Group reiterated a "buy" rating and issued a $420.00 price objective on shares of BeOne Medicines in a report on Monday, November 17th. Finally, Morgan Stanley raised their target price on BeOne Medicines from $350.00 to $383.00 and gave the stock an "overweight" rating in a report on Monday, October 20th. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $365.79.
Check Out Our Latest Report on ONC
Institutional Trading of BeOne Medicines
A number of large investors have recently made changes to their positions in ONC. Primecap Management Co. CA acquired a new stake in BeOne Medicines during the 2nd quarter worth $1,231,720,000. Temasek Holdings Private Ltd acquired a new stake in shares of BeOne Medicines during the second quarter worth about $244,603,000. Marshall Wace LLP bought a new position in shares of BeOne Medicines during the 2nd quarter valued at about $113,190,000. Baird Financial Group Inc. acquired a new position in shares of BeOne Medicines in the 2nd quarter valued at approximately $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in BeOne Medicines during the 2nd quarter worth approximately $73,347,000. Institutional investors own 48.55% of the company's stock.
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
